Lexaria Bioscience Corp. LEXXW
0.00 USD 0.00 (-76.00%)
Jan 13, 2026, 3:20 PM EST
0.0009 Day range 0.0045
0.0009 52-week range 0.0045
- YTD
- 0.00%
- 1 year
- 0.00%
News
benzinga.com Lexaria Bioscience Reports Final Phase 1b GLP-1-H24-4 Results Showing DHT-Semaglutide Demonstrates Comparable Or Improved Safety, Tolerability And Body Composition vs. Rybelsus Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint…
benzinga.com Lexaria Bioscience's DehydraTECH-Semaglutide Shows 48% Reduction In Overall Side Effects And 55% Reduction In Gastrointestinal Side Effects Compared To Rybelsus In Phase 1b Study; Says Recent Financings Support New 2026 Development Opportunities DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®Recent financings…- benzinga.com Lexaria Extends Partnership With PharmaCO To April 2026 For Ongoing Evaluation Of DehydraTECH, Following Australian Study Data Review Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA")…